123 related articles for article (PubMed ID: 22248072)
1. Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas.
Müssig K; Wehrmann T; Dittmann H; Wehrmann M; Ueberberg B; Schulz S; Bares R; Petersenn S
Clin Endocrinol (Oxf); 2012 Jul; 77(1):139-45. PubMed ID: 22248072
[TBL] [Abstract][Full Text] [Related]
2. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.
Tan H; Ye K; Wang Z; Tang H
Jpn J Clin Oncol; 2008 Aug; 38(8):528-33. PubMed ID: 18664479
[TBL] [Abstract][Full Text] [Related]
4. [Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].
Gemsenjäger E; Heitz PU; Martina B; Schweizer I
Praxis (Bern 1994); 2000 Nov; 89(44):1779-97. PubMed ID: 11109916
[TBL] [Abstract][Full Text] [Related]
5. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
6. Correlation of clinicopathological features and expression of molecular markers with prognosis after ¹³¹I treatment of differentiated thyroid carcinoma.
Qin C; Cau W; Zhang Y; Mghanga FP; Lan X; Gao Z; An R
Clin Nucl Med; 2012 Mar; 37(3):e40-6. PubMed ID: 22310269
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronan expression in differentiated thyroid carcinoma.
Böhm J; Niskanen L; Tammi R; Tammi M; Eskelinen M; Pirinen R; Hollmen S; Alhava E; Kosma VM
J Pathol; 2002 Feb; 196(2):180-5. PubMed ID: 11793369
[TBL] [Abstract][Full Text] [Related]
8. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.
Hiltzik D; Carlson DL; Tuttle RM; Chuai S; Ishill N; Shaha A; Shah JP; Singh B; Ghossein RA
Cancer; 2006 Mar; 106(6):1286-95. PubMed ID: 16470605
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
10. [Small thyroid carcinomas: biological characteristics, diagnosis and therapy].
Gemsenjäger E; Schweizer I
Schweiz Med Wochenschr; 1999 May; 129(18):681-90. PubMed ID: 10407941
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
[TBL] [Abstract][Full Text] [Related]
12. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
Wiseman SM; Melck A; Masoudi H; Ghaidi F; Goldstein L; Gown A; Jones SJ; Griffith OL
Ann Surg Oncol; 2008 Oct; 15(10):2811-26. PubMed ID: 18612701
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.
Lang BH; Lo CY; Chan WF; Lam KY; Wan KY
Ann Surg Oncol; 2007 Feb; 14(2):730-8. PubMed ID: 17103065
[TBL] [Abstract][Full Text] [Related]
14. [Differentiated thyroid carcinoma, 1972-1992. Follow-up, detection of recurrences and prognostic factors].
Obiols G; Simó R; Burgos R; Tresserras R; Galofré P; Masmiquel L; Hernández C; Mesa J
Med Clin (Barc); 1997 Nov; 109(19):738-43. PubMed ID: 9470182
[TBL] [Abstract][Full Text] [Related]
15. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma.
Bhattacharyya N
Otolaryngol Head Neck Surg; 2003 Jan; 128(1):115-23. PubMed ID: 12574769
[TBL] [Abstract][Full Text] [Related]
16. Multifactorial analysis of survival and recurrences in differentiated thyroid cancer. Comparative evaluation of usefulness of AGES, MACIS, and risk group scores in Mexican population.
Rodríguez-Cuevas S; Labastida-Almendaro S; Cortés-Arroyo H; López-Garza J; Barroso-Bravo S
J Exp Clin Cancer Res; 2002 Mar; 21(1):79-86. PubMed ID: 12071534
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas.
Furlan JC; Bedard YC; Rosen IB
J Am Coll Surg; 2004 Mar; 198(3):341-8. PubMed ID: 14992733
[TBL] [Abstract][Full Text] [Related]
18. Surgical treatment of papillary and follicular thyroid carcinoma.
Lin JD; Jeng LB; Chao TC; Weng HF; Huang HS
Int Surg; 1996; 81(1):61-6. PubMed ID: 8803709
[TBL] [Abstract][Full Text] [Related]
19. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.
Lundgren CI; Hall P; Dickman PW; Zedenius J
Cancer; 2006 Feb; 106(3):524-31. PubMed ID: 16369995
[TBL] [Abstract][Full Text] [Related]
20. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
